In8bio品牌介绍
品牌简介
IN8bio成立的使命是开发下一代治疗癌症的细胞疗法，是研究γ - δ T细胞领域的领导者。我们正在开发异体、自体、iPSC和转基因γ - δ T细胞疗法。公司在进行的1期和2期临床试验，其中两项针对新诊断的胶质母细胞瘤患者，一项针对接受造血骨髓移植的白血病和淋巴瘤患者。此外，公司还在继续探索其技术在其他治疗组合中的应用。
IN8bio was founded with a
mission to develop the next generation of cell therapies to treat cancer and is
a leader in the field of research into γ - δ T cells. We are developing
allogeneic, autologous, iPSC and transgenic γ - δ T cell therapies. The
company is conducting Phase 1 and Phase 2 clinical trials, including two for
newly diagnosed glioblastoma and one for leukemia and lymphoma patients
undergoing hematopoietic bone marrow transplantation. In addition, the company
continues to explore the application of its technology in other therapeutic
combinations.
Main product
The DeltEx Platform
